Trials / Completed
CompletedNCT01531075
Hepatitis B Vaccine in Patients With Inflammatory Bowel Disease
Assessment of Hepatitis B Vaccination Efficacy in Patients With Inflammatory Bowel Diseases
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 91 (actual)
- Sponsor
- Soroka University Medical Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The objective is to assess the efficacy of Hepatitis B Virus vaccination in a population of IBD patients treated with immunosuppressive medications.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | ENGERIX-B (HBV Vaccine) | ENGERIX-B (Hepatitis B Vaccine) 20 mcg, A series of 3 doses (1 mL each) given on a 0-, 1-, 6-month schedule. |
| BIOLOGICAL | Sci-B-Vac | Sci-B-Vac (Hepatitis B Vaccine) 10 μg/ml, A series of 3 doses (1 mL each) given on a 0-, 1-, 6-month schedule. |
Timeline
- Start date
- 2012-04-01
- Primary completion
- 2015-08-01
- Completion
- 2016-08-01
- First posted
- 2012-02-10
- Last updated
- 2020-04-21
Locations
1 site across 1 country: Israel
Source: ClinicalTrials.gov record NCT01531075. Inclusion in this directory is not an endorsement.